Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations

Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy with a poor prognosis despite the advent of novel therapies. Consequently, a major need exists for new therapeutic options, particularly for patients with relapsed/refractory (R/R) AML. In recent years, it has been possible to indi...

Full description

Bibliographic Details
Main Authors: Beatriz Guijarro-Albaladejo, Cristina Marrero-Cepeda, Eduardo Rodríguez-Arbolí, Belén Sierro-Martínez, José Antonio Pérez-Simón, Estefanía García-Guerrero
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
CAR-T cell
acute myeloid leukemia
immunotherapy
clinical trials
target antigens
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2024.1376554/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2024.1376554/full

Similar Items